These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
205 related articles for article (PubMed ID: 25466627)
1. Role of type I interferon in inducing a protective immune response: perspectives for clinical applications. Rizza P; Moretti F; Capone I; Belardelli F Cytokine Growth Factor Rev; 2015 Apr; 26(2):195-201. PubMed ID: 25466627 [TBL] [Abstract][Full Text] [Related]
2. Interferon-α as antiviral and antitumor vaccine adjuvants: mechanisms of action and response signature. Aricò E; Belardelli F J Interferon Cytokine Res; 2012 Jun; 32(6):235-47. PubMed ID: 22490303 [TBL] [Abstract][Full Text] [Related]
3. IFN-alpha in the generation of dendritic cells for cancer immunotherapy. Santini SM; Lapenta C; Santodonato L; D'Agostino G; Belardelli F; Ferrantini M Handb Exp Pharmacol; 2009; (188):295-317. PubMed ID: 19031032 [TBL] [Abstract][Full Text] [Related]
4. Recent advances on the immunomodulatory effects of IFN-alpha: implications for cancer immunotherapy and autoimmunity. Rizza P; Moretti F; Belardelli F Autoimmunity; 2010 Apr; 43(3):204-9. PubMed ID: 20187707 [TBL] [Abstract][Full Text] [Related]
5. Combination strategies for enhancing the efficacy of immunotherapy in cancer patients. Moschella F; Proietti E; Capone I; Belardelli F Ann N Y Acad Sci; 2010 Apr; 1194():169-78. PubMed ID: 20536466 [TBL] [Abstract][Full Text] [Related]
6. The natural alliance between type I interferon and dendritic cells and its role in linking innate and adaptive immunity. Santini SM; Di Pucchio T; Lapenta C; Parlato S; Logozzi M; Belardelli F J Interferon Cytokine Res; 2002 Nov; 22(11):1071-80. PubMed ID: 12513906 [TBL] [Abstract][Full Text] [Related]
7. Type I interferons as vaccine adjuvants against infectious diseases and cancer. Bracci L; La Sorsa V; Belardelli F; Proietti E Expert Rev Vaccines; 2008 Apr; 7(3):373-81. PubMed ID: 18393607 [TBL] [Abstract][Full Text] [Related]
8. Interferon-alpha and cancer: mechanisms of action and new perspectives of clinical use. Ferrantini M; Capone I; Belardelli F Biochimie; 2007; 89(6-7):884-93. PubMed ID: 17532550 [TBL] [Abstract][Full Text] [Related]
9. IFN-alpha and novel strategies of combination therapy for cancer. Bracci L; Proietti E; Belardelli F Ann N Y Acad Sci; 2007 Sep; 1112():256-68. PubMed ID: 17567945 [TBL] [Abstract][Full Text] [Related]
10. Dendritic cells and cytokines in immune rejection of cancer. Ferrantini M; Capone I; Belardelli F Cytokine Growth Factor Rev; 2008 Feb; 19(1):93-107. PubMed ID: 18054517 [TBL] [Abstract][Full Text] [Related]
11. IFN-α as a vaccine adjuvant: recent insights into the mechanisms and perspectives for its clinical use. Rizza P; Capone I; Moretti F; Proietti E; Belardelli F Expert Rev Vaccines; 2011 Apr; 10(4):487-98. PubMed ID: 21506646 [TBL] [Abstract][Full Text] [Related]
12. Delivery of interferon-alpha transfected dendritic cells into central nervous system tumors enhances the antitumor efficacy of peripheral peptide-based vaccines. Okada H; Tsugawa T; Sato H; Kuwashima N; Gambotto A; Okada K; Dusak JE; Fellows-Mayle WK; Papworth GD; Watkins SC; Chambers WH; Potter DM; Storkus WJ; Pollack IF Cancer Res; 2004 Aug; 64(16):5830-8. PubMed ID: 15313927 [TBL] [Abstract][Full Text] [Related]
13. Nanotechnology-based manipulation of dendritic cells for enhanced immunotherapy strategies. Klippstein R; Pozo D Nanomedicine; 2010 Aug; 6(4):523-9. PubMed ID: 20085824 [TBL] [Abstract][Full Text] [Related]
14. Interferon-alpha (IFN-alpha)-conditioned DC preferentially stimulate type-1 and limit Treg-type in vitro T-cell responses from RCC patients. Gigante M; Mandic M; Wesa AK; Cavalcanti E; Dambrosio M; Mancini V; Battaglia M; Gesualdo L; Storkus WJ; Ranieri E J Immunother; 2008 Apr; 31(3):254-62. PubMed ID: 18317362 [TBL] [Abstract][Full Text] [Related]
15. Are Conventional Type 1 Dendritic Cells Critical for Protective Antitumor Immunity and How? Cancel JC; Crozat K; Dalod M; Mattiuz R Front Immunol; 2019; 10():9. PubMed ID: 30809220 [TBL] [Abstract][Full Text] [Related]
16. Type I interferons and dendritic cells in cancer immunotherapy. Sprooten J; Agostinis P; Garg AD Int Rev Cell Mol Biol; 2019; 348():217-262. PubMed ID: 31810554 [TBL] [Abstract][Full Text] [Related]
17. Fast dendritic cells stimulated with alternative maturation mixtures induce polyfunctional and long-lasting activation of innate and adaptive effector cells with tumor-killing capabilities. Massa C; Seliger B J Immunol; 2013 Apr; 190(7):3328-37. PubMed ID: 23447683 [TBL] [Abstract][Full Text] [Related]
18. Immunization of stage IV melanoma patients with Melan-A/MART-1 and gp100 peptides plus IFN-alpha results in the activation of specific CD8(+) T cells and monocyte/dendritic cell precursors. Di Pucchio T; Pilla L; Capone I; Ferrantini M; Montefiore E; Urbani F; Patuzzo R; Pennacchioli E; Santinami M; Cova A; Sovena G; Arienti F; Lombardo C; Lombardi A; Caporaso P; D'Atri S; Marchetti P; Bonmassar E; Parmiani G; Belardelli F; Rivoltini L Cancer Res; 2006 May; 66(9):4943-51. PubMed ID: 16651452 [TBL] [Abstract][Full Text] [Related]
19. Physiological role of plasmacytoid dendritic cells and their potential use in cancer immunity. Schettini J; Mukherjee P Clin Dev Immunol; 2008; 2008():106321. PubMed ID: 19190769 [TBL] [Abstract][Full Text] [Related]
20. The type I IFN system in rheumatoid arthritis. Conigliaro P; Perricone C; Benson RA; Garside P; Brewer JM; Perricone R; Valesini G Autoimmunity; 2010 Apr; 43(3):220-5. PubMed ID: 20166872 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]